HealthQuill Biopharmaceuticals
Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of 2026, according to a company statement.
Drugs Health Pharma

AstraZeneca to invest $3.5 billion in the US to expand global footprint

Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of.

Read More
An oral investigational drug jointly developed by Biogen Inc., and Sage Therapeutics Inc., failed to stop essential tremors in patients, forcing the companies to halt the trial.
Drugs Health Pharma

Biogen, Sage halt tremor trial after ‘disappointing’ oral drug results

An oral investigational drug jointly developed by Biogen Inc., and Sage Therapeutics Inc., failed to stop essential tremors in patients, forcing the companies.

Read More
Eli Lilly and Company will acquire biopharmaceutical firm, Morphic Holding Inc., for $3.2 billion in cash, giving it access to a molecule inhibitor to treat inflammatory bowel disease.
Drugs Health Pharma

Eli Lilly to buy Morphic for $3.2 b in cash to expand integrin therapies

Eli Lilly and Company will acquire biopharmaceutical firm, Morphic Holding Inc., for $3.2 billion in cash, giving it access to a molecule inhibitor.

Read More
AstraZeneca signed a $245 million deal with a French clinical-stage biotechnology firm, Cellectis, to speed up therapeutics in oncology, immunology and rare diseases.
Drugs Health Pharma

AstraZeneca inks $245 million deal with Cellectis for rare diseases

HQ Team November 1, 2023: AstraZeneca signed a $245 million deal with a French clinical-stage biotechnology firm, Cellectis, to speed up therapeutics in.

Read More